Clinical trials: Sunitinib, completed
Metastatic Renal Cell Cancer
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
This pilot study is an open-label interventional study, prospective, non-comparative, sequential (two stages), national, multicenter study.
- Trial name
- SUP-R (NCT02555748)
- Testing
- Pazopanib, Sunitinib
- Where
- 8 sites in France
- Volunteers
- 47 people
- Sponsor
- Institut Claudius Regaud
Gastrointestinal Stromal Tumors
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
This study will evaluate the preliminary efficacy of nilotinib in pretreated patients (Imatinib, Sunitinib) with unresectable or metastatic gastrointestinal stromal tumors.
- Trial name
- NCT01289028
- Testing
- Nilotinib
- Where
- 19 sites in Germany, Italy
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Renal Cell Carcinoma
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy…
- Trial name
- NCT01265901
- Testing
- Sunitinib, GM-CSF, Cyclophosphamide
- Where
- 105 sites in United States, France and 9 more
- Volunteers
- 339 people
- Sponsor
- Immatics Biotechnologies GmbH
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
OPALINE : A Study Of Morbidity And Mortality At 2 Years
A descriptive, prospective (partly retrospective), multisite, observational study conducted in France in adult patients treated for a well differentiated, unresectable or metastatic, pancreatic neuroendocrine tumor with disease…
- Trial name
- OPALINE (NCT02264665)
- Testing
- sunitinib, everolimus, chemotherapies recommended in france
- Where
- 35 sites in France
- Volunteers
- 144 people
- Sponsor
- Pfizer
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
To investigate safety and efficacy of single agent sunitinib malate in Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor.
- Trial name
- GIST (NCT00793871)
- Testing
- Sunitinib Malate (SU011248)
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Pfizer
Refractory Solid Tumors
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
This study is a single arm, pilot study of Sunitinib in patient with RET fusion positive, FGFR2 fusion/FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following…
- Trial name
- NCT02691793
- Testing
- Sunitinib
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Samsung Medical Center
CNS Cancer, Meningioma
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
The purpose of this study is to find out what effects, good and/or bad, sunitinib has on patients and their tumors. At this time, no drugs are routinely used to treat meningioma, hemangioblastoma or hemangiopericytoma.
- Conditions
- CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma
- Trial name
- NCT00589784
- Testing
- Sunitinib
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
GIST
Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
Retrospective correlation of clinical outcomes data with mutational status in GIST subjects treated with sunitinib.
- Trial name
- NCT01459757
- Testing
- non-interventional
- Where
- 36 sites in United States, Australia and 14 more
- Volunteers
- 322 people
- Sponsor
- Pfizer
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of sunitinib and gemcitabine in treating patients with pancreatic cancer or other solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00462553
- Testing
- sunitinib malate, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma, Kidney Cancer
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
The purpose of this study is to test the safety of RAD-001 and Sunitinib given in combination for renal cell cancer. We also want to find out what effects (good and bad) the combination of RAD-001 and Sunitinib have on you and…
- Trial name
- NCT00422344
- Testing
- RAD001, Sunitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with…
- Trial name
- NCT00113516
- Testing
- carboplatin, paclitaxel, sunitinib
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 84 people
- Sponsor
- Pfizer
Advanced Biliary Tract Adenocarcinoma
Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma
The purpose of this study is to determine whether sunitinib as second-line treatment in advanced biliary tract carcinoma
- Trial name
- NCT01082809
- Testing
- Sunitinib
- Where
- South Korea
- Volunteers
- 59 people
- Sponsor
- Samsung Medical Center
Unresectable or Metastatic Colorectal Cancer
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
To evaluate the efficacy, safety and pharmacokinetics of sunitinib plus FOLFIRI (irinotecan, 5-FU and l-leucovorin) in the first-line treatment of Japanese mCRC patients
- Trial name
- NCT00668863
- Testing
- FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil), Sunitinib
- Where
- 10 sites in Japan
- Volunteers
- 71 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
This non-interventional study includes patients with advanced and/or metastatic renal cell carcinoma who are treated with SUTENT and who did not receive any other systemic therapy before.
- Trial name
- SUNIKA (NCT00460798)
- Testing
- Sutent: observational study
- Volunteers
- 356 people
- Sponsor
- Pfizer
Clear Cell Renal Carcinoma
TroVax Renal Immunotherapy Survival Trial
The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
- Trial name
- NCT00397345
- Testing
- Trovax, Standard of care therapy
- Where
- 152 sites in United States, France and 8 more
- Volunteers
- 733 people
- Sponsor
- Oxford BioMedica
Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter study which aims to determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant…
- Trial name
- FIRSTMAPPP (NCT01371201)
- Testing
- Sunitinib
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 78 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Genitourinary Cancer, Kidney Cancer
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug.
- Trial name
- NCT02060370
- Testing
- Sunitinib, Questionnaire
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Paraganglioma, Pheochromocytoma
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
This is an open-label phase II study of an investigational drug, sunitinib malate in patients with advanced malignant paraganglioma or phaeochromocytoma cancer.
- Trial name
- SNIPP (NCT00843037)
- Testing
- Sunitinib
- Where
- 4 sites in Canada, Netherlands
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Metastatic Renal Cancer
Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma
The purpose of this study is the evaluation of dynamic contrast-enhanced CT (Perfusion-CT) for therapeutic response predicition in patients with metastasized renal carcinoma (mRCC) undergoing antiangiogenetic therapy (AAT) with…
- Trial name
- NCT02086734
- Testing
- Perfusion-CT
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Kidney Cancer
Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01024205
- Testing
- sunitinib malate, laboratory biomarker analysis, adjuvant therapy
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Barts and the London School of Medicine and Dentistry